Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIRx Med

Date Submitted: May 4, 2021
Date Accepted: Jun 24, 2021
Date Submitted to PubMed: Aug 4, 2023

The final, peer-reviewed published version of this preprint can be found here:

Initial SARS-CoV-2 Vaccination Uptake in a Correctional Setting: Cross-sectional Study

Berk J, Murphy M, Chan P, Kane K, Rich J, Brinkley-Rubinstein L

Initial SARS-CoV-2 Vaccination Uptake in a Correctional Setting: Cross-sectional Study

JMIRx Med 2021;2(3):e30176

DOI: 10.2196/30176

PMID: 34658368

PMCID: 8483152

SARS-CoV-2 Vaccination Uptake in a Correctional Setting

  • Justin Berk; 
  • Matthew Murphy; 
  • Phillip Chan; 
  • Kimberly Kane; 
  • Josiah Rich; 
  • Lauren Brinkley-Rubinstein

ABSTRACT

Between December 2020 and February 2021, the Rhode Island Department of Corrections offered SARS-CoV-2 vaccination to all correctional staff and sentenced individuals incarcerated in the state. During this initial campaign, 76.4% (1106 / 1447) of sentenced individuals and 68.4% (1008 / 1474) of correctional staff accepted and received the vaccine. This study demonstrates the feasibility and efficiency of vaccine implementation in a carceral setting.


 Citation

Please cite as:

Berk J, Murphy M, Chan P, Kane K, Rich J, Brinkley-Rubinstein L

Initial SARS-CoV-2 Vaccination Uptake in a Correctional Setting: Cross-sectional Study

JMIRx Med 2021;2(3):e30176

DOI: 10.2196/30176

PMID: 34658368

PMCID: 8483152

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Advertisement